Events Archives - Page 42 of 128

2 minute read

Horizon Therapeutics Plc Announces New UPLIZNA Data In Neuromyelitis Optica Spectrum Disorder To Be presented At ECTRIMS 2023

October 2, 8:14 AM

-- Presentations will feature data from the pivotal Phase 3 study of UPLIZNA, including new biomarker analyses --Horizon Therapeutics plc (NASDAQ:HZNP) today announced that new UPLIZNA analyses will be presented at the

HZNP

3 minute read

The Rise Of The Northeastern Cannabis Market, Profitability And Inclusion At Benzinga Cannabis Capital Conference

By Nicolas Jose Rodriguez

September 28, 7:40 PM

As the Northeast U.S. cannabis market takes the lead in growth potential, questions arise on how the region can transform the industry playbook. Can collaboration between legacy operators and established companies pave the way for a thriving, profitable future?

ACRGF

3 minute read

EXCLUSIVE: Europe Is The Biggest Opportunity For Growth In The Cannabis Sector,’ Curaleaf’s Boris Jordan Tells Benzinga Cannabis Capital Conference

By Joana Scopel

September 28, 5:14 PM

"Europe is the biggest opportunity for growth in the cannabis sector in the next five years," said Boris Jordan, founder and executive chairman of the board of Curaleaf Holdings Inc (OTCQX: CURLF) to the

CURLF

3 minute read

EXCLUSIVE: NY Cannabis Market Optimism Prevails Despite ‘Absurd’ Taxes, Illegal Operators, Lawsuits

By Nina Zdinjak

September 28, 4:58 PM

Ever since the launch of the legal cannabis market in New York last year, the industry has been dealing with one setback after another.

ACRHF

2 minute read

Verastem Presents Avutometinib And Defactinib Combination Program Updates At The 5th Annual RAS-Targeted Drug Development Summit

By Benzinga Newsdesk

September 28, 2:16 PM

Preclinical and Clinical Presentations Include Update on FRAME Study Low-Grade Serous Ovarian Cancer Efficacy DataVerastem Oncology, (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for

VSTM

2 minute read

Curaleaf Ready To Raise CA$16.2M With Securities Offering

By Jelena Martinovic

September 28, 1:12 PM

Curaleaf Holdings Inc (CSE: CURA) (OTCQX: CURLF) announced on Thursday the pricing of its previously announced marketed offering of its subordinate voting shares at CA$6 ($4.43) per security.

CSE:CURA

2 minute read

EXCLUSIVE: How Regulatory Reforms Could Reshape M&A Pulse In Cannabis Industry

By Joana Scopel

September 28, 11:29 AM

The cannabis industry's mergers and acquisitions (M&A) landscape is undergoing a transformation, as highlighted in a recent panel discussion led by Scott Greiper, founder and president at Viridian Capital Advisors, at the Benzinga Cannabis Capital Conference in Chicago.</

VRNOF

2 minute read

EXCLUSIVE: Cannabis CEOs Address How To Attract Investors Amid Changing Regulations

By Nicolas Jose Rodriguez

September 28, 9:50 AM

"The right investors are not scared by the complexity of cannabis regulations," TILT Holdings (CSE: TILT) (OTC: TLLTF) CEO Tim Conder said at the Benzinga Cannabis Capital Conference.

CSE:TILT

1 minute read

EXCLUSIVE: MariMed CEO Discusses Evolving Illinois Cannabis Market, Rescheduling

By Nicolas Jose Rodriguez

September 28, 9:23 AM

Jon Levine, CEO of multi-state cannabis operator, MariMed (OTC: MRMD), and Erik Sloane, Global Head of Corporate Listings at Cboe Canada, discussed the evolving Illinois cannabis market at the

MRMD

1 minute read

Lexicon To Present Post Hoc Analysis Of Scored Clinical Trial At The Heart Failure Society Of America Annual Scientific Meeting 2023

By Benzinga Newsdesk

September 28, 9:11 AM

INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failureSCORED was one of two randomized, double-blind, placebo-controlled Phase 3 cardiovascular outcomes studies that led to FDA approvalTHE

LXRX